Skip to the content
Please enable JavaScript in your browser to complete this form.
Pre-meeting Survey
Please complete this short survey to help us better understand local physicians’ perception and adoption of genetic testing and the treatment landscape for patients with metastatic castration-resistant prostate cancer (mCRPC).
Genetic testing perception and adoption
1. What is your perception regarding the awareness of associating
BRCA
with prostate cancer amongst local physicians? [on a scale of 1–5, with 5 being the highest awareness]
1. What is your perception regarding the awareness of associating BRCA with prostate cancer amongst local physicians? [on a scale of 1–5, with 5 being the highest awareness]
*
1
2
3
4
5
1
Item #1 1
2
Item #1 2
3
Item #1 3
4
Item #1 4
5
Item #1 5
2. How often do you talk to patients about
BRCA
testing in prostate cancer and its therapeutic implications? [on a scale of 1–5, with 5 being the most frequent, i.e. in all eligible patients]
2. How often do you talk to patients about BRCA testing in prostate cancer and its therapeutic implications? [on a scale of 1–5, with 5 being the most frequent, i.e. in all eligible patients]
*
1
2
3
4
5
1
Item #1 1
2
Item #1 2
3
Item #1 3
4
Item #1 4
5
Item #1 5
3. To what extent do you agree with the following statement? ‘Genetic testing results are
essential
for me to guide patient counselling’ [on a scale of 1–5, with 5 representing the highest level of agreement]
3. To what extent do you agree with the following statement? ‘Genetic testing results are essential for me to guide patient counselling’ [on a scale of 1–5, with 5 representing the highest level of agreement]
*
1
2
3
4
5
1
Item #1 1
2
Item #1 2
3
Item #1 3
4
Item #1 4
5
Item #1 5
4. How likely are you to incorporate genetic testing for prostate cancer in your clinical practice? [on a scale of 1-5, 5 it is part of the standard of care]
4. How likely are you to incorporate genetic testing for prostate cancer in your clinical practice? [on a scale of 1-5, 5 it is part of the standard of care]
*
1
2
3
4
5
1
Item #1 1
2
Item #1 2
3
Item #1 3
4
Item #1 4
5
Item #1 5
5. What are the difficulties experienced/anticipated when conducting genetic testing? [you may select more than one]
5. What are the difficulties experienced/anticipated when conducting genetic testing? [you may select more than one]
*
Logistics concerns
Turnover time
Concordance
Failure rate
Unfamiliarity with testing
Time consuming to explain to patients
Others
Others, please specify:
*
6. At what stage of the patient’s journey should
BRCA
testing best be conducted?
6. At what stage of the patient’s journey should BRCA testing best be conducted?
*
When the patient first receives their diagnosis
When the patient is at advanced stages of the disease
When the patient is at advanced stages of the disease with signs of progression with their current treatment
Others
Others, please specify:
*
Current unmet needs and positioning of PARP inhibitors
7. From a physician’s perspective, how would you rank the importance of these
treatment considerations
for patients with mCRPC?
(1 = most important and 6 = least important)
7. From a physician’s perspective, how would you rank the importance of these treatment considerations for patients with mCRPC?
*
1
2
3
4
5
6
Treatment with better efficacy
1
Treatment with better efficacy 1
2
Treatment with better efficacy 2
3
Treatment with better efficacy 3
4
Treatment with better efficacy 4
5
Treatment with better efficacy 5
6
Treatment with better efficacy 6
Treatment with better safety
1
Treatment with better safety 1
2
Treatment with better safety 2
3
Treatment with better safety 3
4
Treatment with better safety 4
5
Treatment with better safety 5
6
Treatment with better safety 6
Treatment monitoring
1
Treatment monitoring 1
2
Treatment monitoring 2
3
Treatment monitoring 3
4
Treatment monitoring 4
5
Treatment monitoring 5
6
Treatment monitoring 6
Cheaper drug cost
1
Cheaper drug cost 1
2
Cheaper drug cost 2
3
Cheaper drug cost 3
4
Cheaper drug cost 4
5
Cheaper drug cost 5
6
Cheaper drug cost 6
Quality of life
1
Quality of life 1
2
Quality of life 2
3
Quality of life 3
4
Quality of life 4
5
Quality of life 5
6
Quality of life 6
Ease of administration
1
Ease of administration 1
2
Ease of administration 2
3
Ease of administration 3
4
Ease of administration 4
5
Ease of administration 5
6
Ease of administration 6
8. Please rank the importance of these
treatment gaps
in managing your patients with mCRPC.
(1 = most important and 5 = least important)
8. Please rank the importance of these treatment gaps in managing your patients with mCRPC.
*
1
2
3
4
5
Efficacy
1
Efficacy 1
2
Efficacy 2
3
Efficacy 3
4
Efficacy 4
5
Efficacy 5
Safety
1
Safety 1
2
Safety 2
3
Safety 3
4
Safety 4
5
Safety 5
Affordability
1
Affordability 1
2
Affordability 2
3
Affordability 3
4
Affordability 4
5
Affordability 5
Ease of administration
1
Ease of administration 1
2
Ease of administration 2
3
Ease of administration 3
4
Ease of administration 4
5
Ease of administration 5
Quality of life
1
Quality of life 1
2
Quality of life 2
3
Quality of life 3
4
Quality of life 4
5
Quality of life 5
9. How would you rate your understanding of PARP inhibitors in mCRPC? For e.g., familiarity with efficacy data, safety data, etc.
9. How would you rate your understanding of PARP inhibitors in mCRPC? For e.g., familiarity with efficacy data, safety data, etc.
*
Extremely familiar
Very familiar
Moderately familiar
Slightly familiar
Not familiar at all
Extremely familiar
Item #1 Extremely familiar
Very familiar
Item #1 Very familiar
Moderately familiar
Item #1 Moderately familiar
Slightly familiar
Item #1 Slightly familiar
Not familiar at all
Item #1 Not familiar at all
10. For which patients with mCRPC would you consider initiating PARP inhibitors?
(Select all that apply)
10. For which patients with mCRPC would you consider initiating PARP inhibitors?
*
Chemotherapy-naive patients who progressed on next-generation hormonal agents (NHAs)
Patients who progressed on both chemotherapy and NHAs
Patients who progressed on 2ⁿᵈ NHA or chemotherapy rechallenged patients (at least 3 lines of prior therapy)
More information is needed before considering PARP inhibitors
Others, please specify
Others
*
Thank you very much for your participation!
Submit
HK-8637